Literature DB >> 19255126

The case for using albuminuria in staging chronic kidney disease.

Ron T Gansevoort1, Paul E de Jong.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19255126     DOI： 10.1681/ASN.2008111212

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  22 in total

Review 1.  Systolic pressure, diastolic pressure, or pulse pressure as a cardiovascular risk factor in renal disease.

Authors:  José A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Authors:  Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

Review 3.  World Kidney Day 2011: protect your kidneys, save your heart.

Authors:  William G Couser; Miguel C Riella
Journal:  Pediatr Nephrol       Date:  2011-01-20       Impact factor: 3.714

4.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

5.  Combined application of eGFR and albuminuria for the precise diagnosis of stage 2 and 3a CKD in the elderly.

Authors:  Conghui Liu; Haiping Chen; Cuiyun Liu; Chen Fu; Hui Zhang; Huayu Yang; Peng Wang; Fan Wang; Shujun Chen; Qing Ma
Journal:  J Nephrol       Date:  2014-03-08       Impact factor: 3.902

6.  Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.

Authors:  David G Warnock; Paul Muntner; Peter A McCullough; Xiao Zhang; Leslie A McClure; Neil Zakai; Mary Cushman; Britt B Newsome; Reshma Kewalramani; Michael W Steffes; George Howard; William M McClellan
Journal:  Am J Kidney Dis       Date:  2010-08-08       Impact factor: 8.860

7.  Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Authors:  Frank Weidemann; Johannes Krämer; Thomas Duning; Malte Lenders; Sima Canaan-Kühl; Alice Krebs; Hans Guerrero González; Claudia Sommer; Nurcan Üçeyler; Markus Niemann; Stefan Störk; Michael Schelleckes; Stefanie Reiermann; Jörg Stypmann; Stefan-Martin Brand; Christoph Wanner; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

8.  Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1.

Authors:  Xiangling Wang; John C Lieske; Mariam P Alexander; Muthuvel Jayachandran; Aleksandar Denic; Jerry Mathew; Lilach O Lerman; Walter K Kremers; Joseph J Larson; Andrew D Rule
Journal:  Am J Nephrol       Date:  2016-06-10       Impact factor: 3.754

9.  Diabetes: Renal benefits of lowering BP in the absence of hypertension.

Authors:  Hiromichi Suzuki
Journal:  Nat Rev Nephrol       Date:  2009-07       Impact factor: 28.314

Review 10.  Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?

Authors:  Luis Ruilope; Joseph Izzo; Hermann Haller; Bernard Waeber; Suzanne Oparil; Michael Weber; George Bakris; James Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-06       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.